Masking, distancing and quarantines keep chimps safe from human disease, study shows
Peer-Reviewed Publication
Updates every hour. Last Updated: 8-Sep-2025 06:11 ET (8-Sep-2025 10:11 GMT/UTC)
Researchers have developed a portable diagnostic system that evaluates an individual’s antibody protection against COVID-19 using just one microliter of fingertip blood. The Tip Optofluidic Immunoassay (TOI) combines high-sensitivity chemiluminescence detection with microfluidic biosensing to assess antibody protection from both pathogen binding and virus inhibition perspectives—all in just 40 minutes. While many platforms measure antibody levels, few capture the functional aspect of immunity: neutralization. TOI incorporates a renovated in vitro inhibition assay (RIVIA), enhanced through rational protein design to achieve high sensitivity and reproducibility. Unlike conventional methods that require large blood volumes and centralized lab facilities, TOI enables comprehensive immune profiling with minimal resources. Validated in over 100 volunteers, the platform shows strong potential for both public health surveillance and personalized immune assessment. This innovation bridges the gap between laboratory diagnostics and real-world healthcare, offering a practical tool for monitoring vaccine effectiveness and tracking immunity against emerging viral variants.
HAEZI group researchers analysed the impact on memory exerted by the declaration of a state of alarm due to COVID. From the accuracy and certainty that respondents revealed in their memories, they concluded that the impact was significant and that to leave a lasting impression an event does not have to be unexpected. They also studied how age influences memories and found that memories become less detailed with the advancing years.
A study by Stanford University and the Institute for Bioengineering of Catalonia describes an innovative technology that enables the large-scale analysis of antibodies in biological samples. Using microscopic beads marked with stable isotopes, this advance surpasses traditional techniques, accelerating the study of immune responses and opening up new possibilities for biomedical research.
A new county-level dataset from Johns Hopkins University researchers reveals a national decline in the measles-mumps-rubella (MMR) vaccination rate among U.S. children since the start of the COVID-19 pandemic. Out of 2,066 studied counties, 1,614 counties, 78%, reported drops in vaccinations and the average county-level vaccination rate fell 93.92% pre-pandemic to 91.26% post-pandemic—an average decline of 2.67%, moving further away from the 95% herd immunity threshold to predict or limit the spread of measles.
Mass General Brigham researchers are shining a powerful new light into the viral darkness with the development of Luminescence CAscade-based Sensor (LUCAS), a rapid, portable, highly-sensitive diagnostic tool for processing complex biological samples. Compared to its diagnostic predecessors, LUCAS creates 500-fold stronger and 8-fold longer-lasting bioluminescence signals, overcoming longstanding challenges faced by point-of-care diagnostics. Their study published today in Nature Biomedical Engineering.